Guangzhou, China – Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended the 18th South China International Congress of Cardiology ("SCC 2016") held in Guangzhou, to promote our in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®").
The SCC 2016 values Science, Creation and Concord. It provides a platform for domestic and international cardiovascular specialists to exchange ideas on new thoughts and breakthroughs in the prevention and treatment of cardiovascular diseases.
During the conference, Professor Bo Xu of Fuwai Hospital delivered a speech on the innovations of cardiovascular devices, in which he released the four-year research results of Firehawk® while announcing that its five-year follow-up studies will be completed this year. He also introduced in particular the TARGET All Comer clinical trial, a prospective, multi-center, randomized clinical trial to evaluate Firehawk®'s safety and efficacy.
Meanwhile, Professor Bo Xu shared the updates of the First-in-Man ("FIM") Clinical Trials of Firesorb™ Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb™"). He presented three successful cases in the FIM clinical trials, one of which showed the implanted scaffold has started resorbing. In addition, Professor Xu gave a brief introduction to Firesorb™ FUTURE II Clinical Trial that is about to launch.